Neonatal Lupus Clinical Trial
Official title:
Preventive IVIG Therapy for Congenital Heart Block (The PITCH Study)
Neonatal lupus (NL) is the name given to a group of conditions that can affect the babies of mothers who have certain autoantibodies against components of the body's cells that are called SSA/Ro and SSB/La. NL can appear as a temporary rash that usually goes away by the time the baby is 6 months old, or very rarely an abnormal blood or liver condition that also improves with time - or it can cause permanent and often life-threatening damage to the fetal heart, known as congenital heart block (CHB). In women with anti-Ro/La antibodies who are pregnant for the first time, only about 2% of the babies will develop CHB. But for a woman who has already had a child with CHB or NL rash, the risk of CHB in her next pregnancy is nearly 20%. Unfortunately, once complete (third degree) heart block has been unequivocally identified in a fetus, it has never been reversed with any of the therapies that have been tried to date. Our previous studies strongly indicate that scarring of the conduction system (the heart's own natural "pacemaker"), a consequence of inflammation triggered by the mother's antibodies, damages or even destroys the cells that allow the heart to beat at a normal rhythm. Instead, the damaged heart beats extremely slowly, to an extent that is fatal to nearly 20% of affected babies (with most deaths occurring as fetal demises). Nearly all surviving children with CHB require permanent implantation of a pacemaker device. Because it is so difficult to treat or repair the damaged heart, a high-priority strategy is to try to prevent the inflammatory process before irreversible scarring can occur. The aim of this clinical-based proposal is to determine whether treating the pregnant mother with intravenous immune globulin (IVIG) will prevent the development of CHB.
Perhaps the strongest clinical association with autoantibodies against SSA/Ro-SSB/La is the
development of congenital heart block (CHB) in an offspring, an alarming prospect facing 2%
of primigravid mothers with these antibodies. Recurrence rates approach 20%. Disease can
progress rapidly, with advanced block and life-threatening cardiomyopathy observed less than
2 weeks from normal sinus rhythm. Once 3rd degree (complete) block is identified, reversal
has never been achieved, despite dexamethasone. This makes biologic sense since the signature
lesion is fibrosis of the atrioventricular node. Thus, strategies aimed at preventing disease
assume high priority. Although disease expression in the fetus requires additional factors to
amplify the cascade to fibrosis, maternal anti-Ro/La antibodies are necessary. Accordingly,
eliminating fetal exposure to these antibodies is a sound and important approach. Intravenous
immune globulin (IVIG) is particularly exciting in its potential not only to lower maternal
antibody levels (which is not accomplished with glucocorticoids or immunosuppression), but
actually to influence effector mechanisms in the fetus itself. Aim 1 is a clinical trial to
assess the efficacy of IVIG in preventing CHB. Proof of efficacy is challenging since CHB
occurs in only 2% of first pregnancies of anti-Ro/La+ women. However, given the 10-fold
higher risk of CHB in a pregnancy after the birth of child with neonatal lupus (NL), mothers
with previous NL-affected children are the target population for study. Sample size
calculations employ Simon's 2-stage optimal design. Based on a 2-sided significance level of
0.05, a power of 90% to show reduction of risk to 5% given the prediction that 18% of
untreated subjects will get some degree of CHB, Stage 1 will enroll 19 women who have had a
previous child with CHB or NL rash, to receive IVIG (400 mg/kg IVIG every 3 weeks for a total
of 5 treatments) from weeks 12 through 24 of gestation. If fewer than 3 mothers have children
with 2nd or 3rd degree block, then an additional 35 mothers will be enrolled in Stage 2
(total = 54 subjects). IVIG will be considered efficacious and worthy of further study if
fewer than 6 of 54 subjects have a child with advanced CHB. Secondary outcomes include 1st
degree block, myocardial injury absent conduction defects, and isolated endocardial
fibroelastosis as assessed by serial fetal echocardiograms and EKG at birth.
Aim 2 will address: a) the effect of IVIG on antibody titer and subclass; b) genetic
polymorphisms in Fc gamma receptor (FcgR) and platelet-activating factor acetylhydrolase and
their potential association with response to IVIG; c) whether a decrease in anti-La
antibodies positively correlates with the level of anti-La antiidiotypic antibodies; d)
whether IVIG blocks expression of activation markers on human macrophages after challenge
with opsonized apoptotic cardiocytes and whether this positively correlates with increased
expression of the inhibitory Fc receptor, FcgRIIb.
In sum, IVIG is a promising agent that may have effects at several levels of the pathologic
cascade to antibody-mediated CHB.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00007358 -
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
|
N/A | |
| Completed |
NCT00074373 -
The Research Registry for Neonatal Lupus
|
||
| Completed |
NCT01379573 -
Preventive Approach to Congenital Heart Block With Hydroxychloroquine
|
Phase 2 | |
| Recruiting |
NCT05958446 -
Fetal-Hope Study: Home Monitoring of Fetal Heart Rate in SSA+ Pregnant Women
|